Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2013 Aug 27:13:130.
doi: 10.1186/1471-2431-13-130.

EURO-WABB: an EU rare diseases registry for Wolfram syndrome, Alström syndrome and Bardet-Biedl syndrome

Affiliations
Observational Study

EURO-WABB: an EU rare diseases registry for Wolfram syndrome, Alström syndrome and Bardet-Biedl syndrome

Amy Farmer et al. BMC Pediatr. .

Abstract

Background: Wolfram, Alström and Bardet-Biedl (WABB) syndromes are rare diseases with overlapping features of multiple sensory and metabolic impairments, including diabetes mellitus, which have caused diagnostic confusion. There are as yet no specific treatments available, little or no access to well characterized cohorts of patients, and limited information on the natural history of the diseases. We aim to establish a Europe-wide registry for these diseases to inform patient care and research.

Methods: EURO-WABB is an international multicenter large-scale observational study capturing longitudinal clinical and outcome data for patients with WABB diagnoses. Three hundred participants will be recruited over 3 years from different sites throughout Europe. Comprehensive clinical, genetic and patient experience data will be collated into an anonymized disease registry. Data collection will be web-based, and forms part of the project's Virtual Research and Information Environment (VRIE). Participants who haven't undergone genetic diagnostic testing for their condition will be able to do so via the project.

Conclusions: The registry data will be used to increase the understanding of the natural history of WABB diseases, to serve as an evidence base for clinical management, and to aid the identification of opportunities for intervention to stop or delay the progress of the disease. The detailed clinical characterisation will allow inclusion of patients into studies of novel treatment interventions, including targeted interventions in small scale open label studies; and enrolment into multi-national clinical trials. The registry will also support wider access to genetic testing, and encourage international collaborations for patient benefit.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cartoon of the Euro-WABB registry project.
Figure 2
Figure 2
Data fields held in the registry.

References

    1. Prevalence of rare diseases: Bibliographic data. 2013. (Orphanet Report Series, Rare Diseases collection, June 2013, Number 1: Listed in alphabetical order of disease or group of diseases). http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_disease....
    1. Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. Official Journal of the European Communities. 2000;L18:1–5. http://ec.europa.eu/health/files/eudralex/vol-1/reg_2000_141/reg_2000_14....
    1. Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions. On Rare Diseases: Europe’s challenges. Commission of the European Communities; http://ec.europa.eu/health/ph_threats/non_com/docs/rare_com_en.pdf.
    1. European Union. Council Recommendation of 8 June 2009 on an action in the field of rare diseases. Official J European Union. 2009;C151:7–10.
    1. Barrett TG, Bundey SE, Macleod AF. Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome. Lancet. 1995;346:1458–1463. doi: 10.1016/S0140-6736(95)92473-6. - DOI - PubMed

Publication types